Ibandronate in Malignant Bone Diseases and Osteoporosis – Preclinical Results | Citedby Results | Onkologie | Karger Publishers

Skip to Main Content

Skip Nav Destination

Ibandronate in Malignant Bone Diseases and Osteoporosis – Preclinical Results

Onkologie (1997) 20 (3): 204–208.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys

S.Y Smith
R.R Recker
M Hannan
R Müller
F Bauss

Bone (2003) 32 (1): 45.

Lifelong administration of high doses of ibandronate increases bone mass and maintains bone quality of lumbar vertebrae in rats

S. Lalla
L. A. Hothorn
N. Haag
R. Bader
F. Bauss

Osteoporosis International (1998) 8 (2): 97.